{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:54:52Z","timestamp":1674644092731},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.jacl.2007.01.004","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T04:06:59Z","timestamp":1253765219000},"page":"74-87","source":"Crossref","is-referenced-by-count":3,"title":["Effect of drugs on high-density lipoprotein"],"prefix":"10.1016","volume":"1","author":[{"given":"James M.","family":"McKenney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2007.01.004_bib1","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from90 056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2007.01.004_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"issue":"suppl 6","key":"10.1016\/j.jacl.2007.01.004_bib6","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2007.01.004_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0002-9149(80)90516-0","article-title":"Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols","volume":"46","author":"Wilson","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.jacl.2007.01.004_bib10","first-page":"S4","article-title":"Standards of medical care in diabetes","volume":"28","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2007.01.004_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000114834.85476.81","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women","volume":"109","author":"Mosca","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib12","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2007.01.004_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression on coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2007.01.004_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.jacl.2007.01.004_bib19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.amjcard.2005.09.078","article-title":"Relationship between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial)","volume":"97","author":"Goldenberg","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jacl.2007.01.004_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib26","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib27","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial biology for the investigation of the treatment effects of reducing cholesterol (Arbiter) 2","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib29","first-page":"I-635","article-title":"Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year familial atherosclerosis treatment study (FATS) follow-up","volume":"98","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin an extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2007.01.004_bib31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2007.01.004_bib32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2007.01.004_bib33","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib34","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activates PPAR[graphic] and induces HDL apoA-I","volume":"107","author":"Martin","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2007.01.004_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199801083380203","article-title":"The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis","volume":"338","author":"Kuivenhoven","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (Stellar Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00149-1","article-title":"Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients","volume":"164","author":"Asztalos","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2007.01.004_bib39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.271.9.672","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib41","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib43","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/hq1001.096624","article-title":"Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol","volume":"21","author":"Sakai","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2007.01.004_bib44","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","article-title":"Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by hep G2 cells","volume":"17","author":"Jin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2007.01.004_bib45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjcard.2004.05.021","article-title":"Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B or I","volume":"94","author":"Superko","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2006.04.011","article-title":"Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease","volume":"98","author":"Kuvin","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib47","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanisms of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Steals","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.ATV.0000163844.07815.c4","article-title":"Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in the liver X receptor-dependent manner","volume":"25","author":"Arakawa","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2007.01.004_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5551\/jat.11.278","article-title":"Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men\u2014a nuclear magnetic resonance study","volume":"11","author":"Ikewaki","year":"2004","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2007.01.004_bib50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2003.10.016","article-title":"Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia","volume":"172","author":"Ooi","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2007.01.004_bib51","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib53","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/eurheartj\/ehi184","article-title":"Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia","volume":"26","author":"Petersson","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2007.01.004_bib54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00614301","article-title":"Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolemia","volume":"30","author":"Weisweiler","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2007.01.004_bib55","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacl.2007.01.004_bib56","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2007.01.004_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14740338.5.1.145","article-title":"Satatin\/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions","volume":"5","author":"Davidson","year":"2006","journal-title":"Exp Opin Drug Saf"},{"key":"10.1016\/j.jacl.2007.01.004_bib58","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/CIRCULATIONAHA.105.593855","article-title":"Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport","volume":"113","author":"Duffy","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib59","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2007.01.004_bib60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/01.hco.0000126582.27767.87","article-title":"Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection","author":"Meyers","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.hco.0000126979.41946.7e","article-title":"High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study","volume":"19","author":"Asztalos","year":"2004","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib62","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1161\/CIRCULATIONAHA.104.475715","article-title":"Macrophage reverse cholesterol transport","volume":"113","author":"Cuchel","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","article-title":"Pharmacologic activation of liver X receptors promotes reverse cholesterol transport in vivo","volume":"113","author":"Naik","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib64","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1161\/01.CIR.0000160860.36911.BD","article-title":"Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition","volume":"111","author":"Forrester","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2007.01.004_bib65","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2007.01.004_bib66","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with low-high-density lipoprotein cholesterol levels","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib67","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.jacc.2006.06.066","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels on a background of atorvastatin","volume":"48","author":"McKenney","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2007.01.004_bib68","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.jacl.2007.01.004_bib69","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2007.01.004_bib70","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors of nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunau","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jacl.2007.01.004_bib71","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0006-291X(03)00342-5","article-title":"Molecular idenificati of nicotinic acid receptor","volume":"303","author":"Soga","year":"2003","journal-title":"Biochem Biophy Res Commun"},{"key":"10.1016\/j.jacl.2007.01.004_bib72","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid\u2212induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2007.01.004_bib73","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid","volume":"115","author":"Pike","year":"2005","journal-title":"J Clin Invest"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287407000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287407000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T16:33:18Z","timestamp":1558542798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287407000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1933287407000050"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2007.01.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}